Auto-injectors offer several advantages such as safe, easy, and reliable self-administration. Most auto-injectors are spring-loaded syringes and are categorized as prefilled auto-injectors and fillable auto-injectors.

The global auto-injectors market is estimated to account for US$ 2,338.2 Mn in 2018 in terms of value and is expected to reach US$ 7,894.6 Mn by the end of 2027.

Global Auto-Injectors Market: Drivers

Increasing preference for self-administration of injections is expected to propel growth of the global auto-injectors market over the forecast period. Auto-injectors are easy to use and are intended for self-administration by patients, or administration by untrained personnel. Its passive safety mechanism also prevents accidental firing (injection). Moreover, use of auto-injectors also reduces phobia anxiety associated to needles, which has effectively increased their demand.

Global Auto-Injectors Market: Opportunities 

In Europe, expansion of contract manufacturing facilities dealing with sterile drugs and having proper certifications for product development is expected to offer lucrative growth opportunities for players in the market.

Global Auto-Injectors Market: Restraints  

Availability of alternatives such as nasal spray is expected to hinder growth of the market. For instance, in October 2019, Bryn Pharma, LLC reported that patients prefer bi-dose epinephrine nasal spray over Epipen auto injector. The company presented the related data at the American Academy of Pediatrics (AAP) National Conference & Exhibition.

Key Takeaways:

The prefilled auto-injectors sub segment in product type segment in the global auto-injectors market was valued at US$ 1,904.1 Mn in 2018 and is expected to reach US$ 7,266.6 by 2027 at a CAGR of 15.1% during the forecast period. Prefilled auto injectors are injectable products and several products such as monoclonal antibodies have been introduced in the market which are available in prefilled auto injectors.        

The anaphylaxis sub segment in indication segment held dominant position in the global auto-injectors market in 2018, accounting for 89.2% share in terms of value, followed by multiple sclerosis and rheumatoid arthritis, respectively.

Increasing initiatives by companies to make auto-injectors available to patients suffering from anaphylaxis is expected to boost global auto-injectors market. For instance, Mylan N.V. provides discount cards to epinephrine buyers, and offers discounts up to US$ 300 on branded version of EpiPen and up to US$ 25 on the approved generic version of EpiPen.       

The online pharmacies sub segment in distribution channel segment held dominant position in the global auto-injectors market in 2018, accounting for 35.7% share in terms of value. Online pharmacies offer variety of discount on the products, as well as people can buy these products from home which is expected to support growth of the segment over the forecast period.

Market Trends

Major airlines are stocking epinephrine auto-injectors in their emergency medical kits. For instance, in December 2019, Kaléo collaborated with HealthFirst and MedAire, emergency medical kit distributors, to offer Auvi-Q 0.3 mg and Auvi-Q 0.15 mg auto-injectors in the American Airlines’ emergency medical kits.

The market is also witnessing decrease in the prices of auto-injectors. For instance, in December 2018, Kaléo announced to offer an authorized generic of its EVZIO (naloxone HCl injection) take home naloxone product at a list price of US$ 178 per carton of two auto-injectors.

Regulations

Europe

Auto-injectors fall under medical devices in integral Drug-Device Combinations (DDCs). Integral DDCs are products falling under the second sub-paragraphs of both Article 1(8) and Article 1(9) of the Regulation (EU) 2017/745 on medical devices (the MDR). These Articles describe the two types of integral drug-device combination products authorised under the medicines’ framework:

  • Devices that when placed on the market or put into service incorporate, as an integral part, a substance that, if used separately, would be considered as a medicinal product, provided that the action of the substance is principal (Article 1(8) MDR).
  • Devices intended to administer a medicinal product, where they form a single integral product intended exclusively for use in the given combination and which is not reusable (Article 1(9) MDR). Typically, these devices have measuring, metering or delivery functions.

Global Auto-Injectors Market: Competitive Landscape

Major players operating in the global auto-injectors market include, Becton, Dickinson and Company, Sanofi, Pfizer, Inc., Mylan N.V., Novartis AG, Bayer AG, Janssen Global Services, LLC, Antares Pharma, Inc., Amgen Inc., and Eli Lilly and Company.

Global Auto-Injectors Market: Key Development 

  • August 2019: ALK launched new epinephrine auto-injector that is designed to be small, easy-to-use, heat-stable, and with a long shelf life, in the U.S.
  • September 2019, Emergent BioSolutions Inc. received around US$ 20 million to develop and manufacture an auto-injector containing diazepam (5 mg/mL) for the treatment of nerve agent-induced seizures.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us: